Lupin Introduces Mirabegron Extended-Release Tablets in Us
Overview
Global pharma major Lupin Limited (Lupin) announced the launch of the United States Food and Drug Administration (FDA) approved mirabegron extended-release tablets, 50 mg, in US.
Mirabegron extended-release tablets, 50 mg is a generic equivalent of Myrbetriq extended-release tablets, 50 mg of Astellas Pharma Global Development, Inc.
Estimated Annual Sale
Mirabegron extended-release tablets, 50 mg had estimated annual sales of USD 1,600 million in the US (IQVIA MAT July 2024).
About Lupin Limited
Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets.
Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients.
Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the US across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health.